Tonix Pharmaceuticals Holding Corp. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

SALE AND PURCHASE OF COMMON STOCK (Details Narrative)

SALE AND PURCHASE OF COMMON STOCK (Details Narrative) - USD ($)											3 Months Ended			6 Months Ended
	Jun. 27, 2024	Jun. 12, 2024	Apr. 01, 2024	Mar. 28, 2024	Dec. 20, 2023	Oct. 03, 2023	Aug. 01, 2023	Jul. 27, 2023	Aug. 16, 2022	Apr. 08, 2020	Jun. 30, 2024	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2024	Jun. 30, 2023	May 22, 2024	Jan. 25, 2024	Dec. 31, 2023
Stock offering expenses														$ 1,704,000	$ 137,000
Common stock, authorized											1,000,000,000			1,000,000,000			1,000,000,000	160,000,000
Value of shares issued											$ 10,730,000	$ 1,029,000	$ 1,995,000
Repurchase of common stock															$ 13,965,000
2022 Share Repurchase Program [Member]
Shares repurchased													78,502
Share repurchase authorized amount													$ 12,500,000
Repurchase of common stock													$ 12,500,000
2022 Share Repurchase Program [Member] \| Minimum [Member]
Price per share													$ 88.00
2022 Share Repurchase Program [Member] \| Maximum [Member]
Price per share													$ 275.52
2023 Share Repurchase Program [Member]
Shares repurchased													5,000
Share repurchase authorized amount													$ 12,500,000
Price per share													$ 227.84
Repurchase of common stock													$ 1,100,000
Pre-Funded Warrants [Member]
Number of warrants exercised														3,383,792
Common Warrants [Member]
Number of shares for common warrants			217,188
Exercise price			$ 10.56													$ 10.56
Termination date			Apr. 01, 2029
Common Warrants Series A [Member]
Number of shares for common warrants			278,125
Termination date			Apr. 01, 2029
Common Warrants Series B [Member]
Number of shares for common warrants			278,125
Termination date			Apr. 01, 2025
Common Warrants Series C [Member]
Number of shares for common warrants			1,088,248
Termination date			Apr. 01, 2026
Period of trading days after FDA acceptance of NDA for warrant expiration			10 days
Common Warrants Series D [Member]
Number of shares for common warrants			1,088,248
Termination date			Apr. 01, 2029
Purchase Agreement [Member]
Number of shares issued	2,833,900	1,199,448			791,977
Price per share	$ 0.57	$ 1.065
Stock offering expenses	$ 500,000	$ 500,000
Placement agent fees	300,000	300,000
Net proceeds	$ 3,500,000	$ 3,500,000
Proceeds from equity offerings					$ 30,000,000
Purchase Agreement [Member] \| Common Stock, Pre-funded Warrants and Equity Classified Common Warrants D [Member]
Stock offering expenses					1,400,000
Proceeds from equity offerings					$ 7,500,000
Purchase Agreement [Member] \| Pre-Funded Warrants [Member]
Number of shares for common warrants	4,228,158	2,568,110			897,213
Price per share	$ 0.5699	$ 1.064			$ 17.7568
Exercise price					$ 0.0001
Number of warrants exercised					203,407
Purchase Agreement [Member] \| Common Warrants [Member]
Price per share					$ 17.76
Purchase Agreement [Member] \| Common Warrants Series C [Member]
Number of shares for common warrants					2,533,784
Exercise price					$ 17.76
Warrants term					2 years
Period of trading days after FDA acceptance of NDA for warrant expiration					10 days
Proceeds from equity offerings					$ 14,400,000
Common stock, authorized for warrant exercise					1,000,000,000
Period of trading days after approval date to become exercisable					10 days
Purchase Agreement [Member] \| Common Warrants Series D [Member]
Number of shares for common warrants					2,533,784
Exercise price					$ 27.20
Warrants term					5 years
Purchase Agreement [Member] \| Equity Classified Common Warrants D [Member]
Number of shares for common warrants					1,591,665
Purchase Agreement [Member] \| Liability Classified Common Warrants C and D [Member]
Number of shares for common warrants					942,120
Stock offering expenses					$ 900,000
Purchase Agreement [Member] \| Liability Classified Common Warrants D [Member]
Proceeds from equity offerings					8,100,000
Sales Agreement [Member]
Number of shares issued				336,459		126,563		79,062
Price per share				$ 9.60
Stock offering expenses				$ 500,000	$ 2,300,000	$ 500,000	$ 700,000
Placement agent fees				300,000		300,000	500,000
Net proceeds				$ 3,900,000		$ 4,000,000	$ 6,300,000
Offset to proceeds from issuance of warrants														$ 3,000,000
Sales Agreement [Member] \| Alliance Global Partners [Member]
Number of shares issued												13,766			29,855
Net proceeds												$ 1,000,000			$ 3,000,000
Offering price per agreement										$ 320,000,000
Commission to agent										3.00%
Sales Agreement [Member] \| Pre-Funded Warrants [Member]
Number of shares for common warrants				121,875		154,687		139,688
Price per share				$ 9.5968		$ 15.99		$ 31.99
Sales Agreement [Member] \| Common Warrants Series E [Member]
Number of shares for common warrants				458,334
Exercise price				$ 10.56
Warrants term				5 years 6 months
Sales Agreement [Member] \| Common Warrants [Member]
Number of shares for common warrants								218,750
Price per share						$ 16.00		$ 32.00
Exercise price								$ 32.00
Sales Agreement [Member] \| Common Warrants Series A [Member]
Number of shares for common warrants						281,250
Exercise price						$ 16.00
Warrants term						5 years
Sales Agreement [Member] \| Common Warrants Series B [Member]
Number of shares for common warrants						281,250
Exercise price						$ 16.00
Warrants term						1 year
Purchase Agreement with Lincoln Park 2022 [Member]
Number of shares issued												0			3,000
Net proceeds												$ 0			$ 400,000
Purchase Agreement with Lincoln Park 2022 [Member] \| Lincoln Park Capital Fund, LLC [Member]
Number of shares issued									3,125
Common stock, to be issued									$ 50,000,000
Value of shares issued									$ 1,000,000